These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18594477)

  • 1. Treatment of coronary spastic angina with a statin in addition to a calcium channel blocker: a pilot study.
    Tani S; Nagao K; Anazawa T; Kawamata H; Furuya S; Takahashi H; Iida K; Fuji T; Matsumoto M; Kumabe T; Sato Y; Hirayama A
    J Cardiovasc Pharmacol; 2008 Jul; 52(1):28-34. PubMed ID: 18594477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function.
    Wassmann S; Faul A; Hennen B; Scheller B; Böhm M; Nickenig G
    Circ Res; 2003 Oct; 93(9):e98-103. PubMed ID: 14551237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study).
    Tung P; Wiviott SD; Cannon CP; Murphy SA; McCabe CH; Gibson CM
    Am J Cardiol; 2009 Apr; 103(8):1056-60. PubMed ID: 19361589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers.
    Yasue H; Mizuno Y; Harada E; Itoh T; Nakagawa H; Nakayama M; Ogawa H; Tayama S; Honda T; Hokimoto S; Ohshima S; Hokamura Y; Kugiyama K; Horie M; Yoshimura M; Harada M; Uemura S; Saito Y;
    J Am Coll Cardiol; 2008 May; 51(18):1742-8. PubMed ID: 18452779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of withdrawal of pravastatin therapy on C-reactive protein and low-density lipoprotein cholesterol.
    van der Harst P; Asselbergs FW; Hillege HL; Bakker SJ; Voors AA; van Veldhuisen DJ; van Gilst WH;
    Am J Cardiol; 2007 Nov; 100(10):1548-51. PubMed ID: 17996517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the antiatherosclerotic effects of dihydropyridine calcium channel blocker and HMG-CoA reductase inhibitor on hypercholesterolemic rabbits.
    Takayama M; Matsubara M; Arakawa E; Takada C; Ina Y; Hasegawa K; Yao K
    Vascul Pharmacol; 2007 Apr; 46(4):302-8. PubMed ID: 17197250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of plasma level of malondialdehyde-modified low-density lipoprotein with coronary plaque morphology in patients with coronary spastic angina: implication of acute coronary events.
    Tani S; Nagao K; Anazawa T; Kawamata H; Furuya S; Fuji T; Takahashi H; Iida K; Matsumoto M; Kumabe T; Sato Y; Hirayama A
    Int J Cardiol; 2009 Jun; 135(2):202-6. PubMed ID: 18614250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
    Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study).
    Cui Y; Watson DJ; Girman CJ; Shapiro DR; Gotto AM; Hiserote P; Clearfield MB
    Am J Cardiol; 2009 Sep; 104(6):829-34. PubMed ID: 19733719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
    Ray KK; Cannon CP; Cairns R; Morrow DA; Ridker PM; Braunwald E
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):424-30. PubMed ID: 19122170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
    Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
    Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of type IIb familial combined hyperlipidemia with the combination pravastatin-piperazine sultosilate.
    Masana L; Villoria J; Sust M; Ros E; Plana N; Pérez-Jiménez F; Franco M; Oliván JJ; Pintó X; Videla S
    Eur J Pharmacol; 2004 Aug; 496(1-3):205-12. PubMed ID: 15288592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of statin medications on prostate-specific antigen levels.
    Hamilton RJ; Goldberg KC; Platz EA; Freedland SJ
    J Natl Cancer Inst; 2008 Nov; 100(21):1511-8. PubMed ID: 18957682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
    Teoh H; Mendelsohn AA; Goodman SG; Jaffer S; Chen RY; Tjia S; Theriault L; Langer A; Leiter LA;
    Am J Cardiol; 2009 Sep; 104(6):798-804. PubMed ID: 19733714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Must the medical treatment of vasospastic angina be continued indefinitely?].
    Waters DD; Chaitman BR; Szlachcic J; Théroux P
    Arch Mal Coeur Vaiss; 1983 Feb; 76 Spec No():161-8. PubMed ID: 6407439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin use is associated with decreased CD-40 ligand expression on T lymphocytes of coronary atheroma plaque in patients with stable coronary artery disease.
    Türk U; Alioğlu E; Tengiz I; Ercan E; Mahmudov R; Duygu H; Türkoğlu C
    Anadolu Kardiyol Derg; 2008 Apr; 8(2):99-103. PubMed ID: 18400628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Improvements in insulin sensitivity and inflammatory markers are induced by pravastatin in nondiabetic subjects with hypercholesterolemia.
    Lee WJ; Lee WL; Tang YJ; Liang KW; Chien YH; Tsou SS; Sheu WH
    Clin Chim Acta; 2008 Apr; 390(1-2):49-55. PubMed ID: 18201563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.